(Q73690540)
Statements
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer (English)
G R Hudes
F Nathan
C Khater
N Haas
M Cornfield
B Giantonio
R Greenberg
L Gomella
S Litwin
E Ross
S Roethke
1 September 1997